Digital Breast Tomosynthesis (DBT) & TRICARE

CURRENT TRICARE COVERAGE POLICY
TRICARE updated their policy to include diagnostic DBT (CPT 77061 and 77062 or G0279) on January 25, 2019. TRICARE declined to cover screening indications for DBT since this exam is not yet recommended by the United States Preventive Services Task Force (USPSTF).

COVERAGE STATISTICS AND PATIENT ACCESS
93% of women aged 40-74 have insurance coverage for screening DBT including Medicare, Medicaid, Veterans Health Administration and commercial payers (including United, Aetna, Anthem, Cigna, Humana).

The Federal Government is now requiring women with dense breasts to be notified and DBT offers superior cancer detection for dense breasts.

DBT is available in all 50 states and has become the standard of care for mammography.

TRICARE is the only national payer that does not cover screening DBT, creating a lower standard of care for the women who serve in our armed forces.

WHAT IS DBT?
DBT is Food and Drug Administration (FDA) approved for use in breast cancer screening. DBT is an important innovation which addresses the main limitations of older 2D mammograms by allowing radiologists to examine breast tissue layer by layer. DBT has been found to increase breast cancer detection and reduce unnecessary recalls from screening.

There are over 250 peer reviewed clinical studies proving the clinical and cost effectiveness of DBT. Research has demonstrated the following results:

- Better, earlier breast cancer detection for women of all ages and breast densities
- A greatly reduced chance of callbacks up to 40%
- Detection of 20-65% more invasive breast cancer compared to 2D mammography alone

CONGRESS SHOULD GRANT COVERAGE OF SCREENING DBT TO TRICARE BENEFICIARIES